On May 16, 2013, Codexis, Inc. announced that David Anton, Ph.D., the company's Senior Vice President, BioIndustrials, would transition to a non-executive officer position with the company, effective June 1, 2013.

Codexis, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: David D. O'Toole, Chief Financial Officer, Principal Accounting Officer and Senior Vice President, John J. Nicols, Chief Executive Officer, President and Director, Peter Seufer-Wasserthal, Senior Vice President of Pharmaceuticals.

Codexis, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's revenues were $11.5 million compared with $31.1 million a year ago. Loss from operations was $9.6 million compared with $7.3 million a year ago. Loss before provision (benefit) for income taxes was $9.7 million compared with $7.3 million a year ago. Net loss was $9.6 million or $0.25 per basic and diluted share compared with $7.5 million or $0.21 per basic and diluted share a year ago. The company do expect that cash burn for the second quarter will be higher than cash burn for the first quarter. The company reaffirmed its prior outlook for the full year 2013. Total pharmaceutical revenues are expected in the range of $35 million to $40 million, with approximately $30 million of that total in product revenue. Product gross margin is expected to be in the range of 30% to 35%, and total gross margin for pharmaceutical revenue of approximately 50%. Regarding cash burn, the company continues to expect cash burn in the range of $12 million to $16 million for the year.